The UK-US pharma deal removes tariffs, boosts NHS access to innovative medicines, and drives significant life-sciences investment, safeguarding patients and industry growth.
The UK Health Security Agency (UKHSA) has recently launched a genomic surveillance programme to monitor the hepatitis C virus (HCV) and its response to treatment.
After the NHS announced the launch of their first ever breast cancer screening campaign, tens of thousands of women have been accessing vital advice on attending mammograms.
Professor David Sebag-Montefiore outlines the profound impact of radiotherapy research. Through global trials and personalised approaches, innovation advances cancer care. Collaborative efforts ensure patient-centred treatments, paving the way for smarter, kinder therapies and a future of precision oncology.
Recently, a study that was published in Nature Mental Health showed concerns about the use of acetaminophen during pregnancy and its potential link to the development of attention-deficit/hyperactivity disorder (ADHD) in children.
A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS for children and adults living with Lennox–Gastaut syndrome (LGS).
Trevor Graham, Professor of Genomics and Evolution and the Director of the Centre for Evolution and Cancer at the Institute of Cancer Research, London, describes efforts to incorporate genome sequencing for cancer detection and treatment.
We all have a unique face, fingerprint, voice, and signature, so why wouldn’t we have a unique response to the medicine and treatments we receive? Mark Hitchman, Managing Director at Canon Medical Systems UK, explores this question.
Our bones are designed to remodel themselves; this is a lifelong process involving the bones adjusting to maintain strength, repair damages, and react to specific stress'.
Rachael Lee, Acting Programme Manager of the National Wound Care Strategy Programme (NWCSP), discusses the challenges in wound care provision and the efforts to...
A new treatment, Sotatercept, for pulmonary arterial hypertension (PAH) has recently been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Tarlatamaba, a new treatment for adult patients with small cell lung cancer (SCLC), has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Infections are the second leading cause of death in cancer patients, after the cancer itself; Zisis Kozlakidis and Shalini Jayasekar Zurn discuss the challenges surrounding the interplay between cancer and antimicrobial resistance (AMR).
